非小细胞肺癌脑膜转移诊疗现状

Leptomeningeal metastasis (LM) is one of the disastrous events in managing advanced non-small cell lung cancer (NSCLC) due to severe clinical symptoms and a grave prognosis.Although intrathecal (IT) chemotherapy show some effects for LM in advanced NSCLC, the prognosis is still poor (12 wk-14 wk).A...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000085/
https://www.ncbi.nlm.nih.gov/pubmed/26483335
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.05
_version_ 1783331612854845440
collection PubMed
description Leptomeningeal metastasis (LM) is one of the disastrous events in managing advanced non-small cell lung cancer (NSCLC) due to severe clinical symptoms and a grave prognosis.Although intrathecal (IT) chemotherapy show some effects for LM in advanced NSCLC, the prognosis is still poor (12 wk-14 wk).A large majority (84%-97%) of the patients were found to have adenocarcinoma histology.Epidermal growth factor receptor (EGFR) senstive mutations were detected in 43.0%-70.5% adenocarcinoma patients with LM.EGFR tyrosine kinase inhibitors (TKIs) showed to be effective for LM in selected NSCLC patients in some reseaches, and confer a survival benefit.Furthermore, future trials need be done to determine the effect of EGFR-TKIs treatment in NSCLC-LM patients.
format Online
Article
Text
id pubmed-6000085
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60000852018-07-06 非小细胞肺癌脑膜转移诊疗现状 Zhongguo Fei Ai Za Zhi 综述 Leptomeningeal metastasis (LM) is one of the disastrous events in managing advanced non-small cell lung cancer (NSCLC) due to severe clinical symptoms and a grave prognosis.Although intrathecal (IT) chemotherapy show some effects for LM in advanced NSCLC, the prognosis is still poor (12 wk-14 wk).A large majority (84%-97%) of the patients were found to have adenocarcinoma histology.Epidermal growth factor receptor (EGFR) senstive mutations were detected in 43.0%-70.5% adenocarcinoma patients with LM.EGFR tyrosine kinase inhibitors (TKIs) showed to be effective for LM in selected NSCLC patients in some reseaches, and confer a survival benefit.Furthermore, future trials need be done to determine the effect of EGFR-TKIs treatment in NSCLC-LM patients. 中国肺癌杂志编辑部 2015-10-20 /pmc/articles/PMC6000085/ /pubmed/26483335 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.05 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
非小细胞肺癌脑膜转移诊疗现状
title 非小细胞肺癌脑膜转移诊疗现状
title_full 非小细胞肺癌脑膜转移诊疗现状
title_fullStr 非小细胞肺癌脑膜转移诊疗现状
title_full_unstemmed 非小细胞肺癌脑膜转移诊疗现状
title_short 非小细胞肺癌脑膜转移诊疗现状
title_sort 非小细胞肺癌脑膜转移诊疗现状
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000085/
https://www.ncbi.nlm.nih.gov/pubmed/26483335
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.05

Ejemplares similares